InducTION of mage-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma

Head and Neck

Volumn 34, Issue 12, 2012, Pages 1734-1746

  Voskens, Caroline J ^a   Sewell, Duane ^b,c   Hertzano, Ronna ^b   Desanto, Jennifer ^b   Rollins, Sandra ^b   Lee, Myounghee ^b   Taylor, Rodney ^b   Wolf, Jeffrey ^b   Suntharalingam, Mohan ^b   Gastman, Brian ^d   Papadimitriou, John C ^b   Lu, Changwan ^c   Tan, Ming ^b   Morales, Robert ^c   Cullen, Kevin ^c   Celis, Esteban ^e   Mann, Dean ^b   Strome, Scott E ^b,c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

HLA I; HLA II; immune response; SCCHN; vaccine

Indexed keywords

COMPLEMENTARY DNA; DNA; EPITOPE; FURIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; MELANOMA ANTIGEN; MELANOMA ANTIGEN E A3; MONTANIDE ISA 51; RNA; STEROID; TRANSACTIVATOR PROTEIN; TROJAN PEPTIDE VACCINE; UNCLASSIFIED DRUG; VACCINE;

ADULT; ADVANCED CANCER; AGED; AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BLEEDING; BRAIN EDEMA; BRAIN METASTASIS; CHILL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CRANIAL NEUROPATHY; DEHYDRATION; DIARRHEA; DIPLOPIA; DISEASE COURSE; DRUG WITHDRAWAL; DYSPNEA; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GOUT; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HLA TYPING; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; INFECTION; INJECTION SITE PAIN; MALE; MOTOR NEUROPATHY; NAUSEA; NONHUMAN; PAIN; PHASE 1 CLINICAL TRIAL; PILOT STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIDE EFFECT; VACCINATION; VOMITING;

ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; EPITOPES; EPITOPES, T-LYMPHOCYTE; FEMALE; HEAD AND NECK NEOPLASMS; HLA-A2 ANTIGEN; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PAPILLOMAVIRUS INFECTIONS; PILOT PROJECTS; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC; VIRUS ACTIVATION;

EID: 84869495028     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.22004     Document Type: Article

References (36)

1. Ahmed SM, Cohen EE,. Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors. Curr Cancer Drug Targets 2007; 7: 666-673.
2. Voskens CJ, Strome SE, Sewell DA,. Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome. Curr Mol Med 2009; 9: 683-693.
3. Rosenberg SA, Yang JC, Restifo NP,. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-915.
4. Zwaveling S, Ferreira Mota SC, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002; 169: 350-358.
5. Hoffmann TK, Bier H, Whiteside TL,. Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2004; 53: 1055-1067.
6. Lu J, Wettstein PJ, Higashimoto Y, Appella E, Celis E,. TAP-independent presentation of CTL epitopes by Trojan antigens. J Immunol 2001; 166: 7063-7071.
7. Lu J, Higashimoto Y, Appella E, Celis E,. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol 2004; 172: 4575-4582.
8. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T,. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995; 182: 689-698.
9. Settle K, Posner MR, Schumaker LM, et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res 2009; 2: 776-781.
10. Strome SE, Savva A, Brissett AE, et al. Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations. Clin Cancer Res 2002; 8: 1093-1100.
11. Kenter GG, Welters MJ, Valentijn AR, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008; 14: 169-177.
12. Ressing ME, Sette A, Brandt RM, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A0201-binding peptides. J Immunol 1995; 154: 5934-5943.
13. van der Burg SH, Ressing ME, Kwappenberg KM,. et al. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 2001; 91: 612-618.
14. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-1647.
15. Kienstra MA, Neel HB, Strome SE, Roche P,. Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck 2003; 25: 457-463.
16. Kobayashi H, Song Y, Hoon DS, Appella E, Celis E,. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res 2001; 61: 4773-4778.
17. Pichichero ME,. Improving vaccine delivery using novel adjuvant systems. Hum Vaccin 2008; 4: 262-270.
18. Weinman EC, Roche PC, Kasperbauer JL, et al. Characterization of antigen processing machinery and survivin expression in tonsillar squamous cell carcinoma. Cancer 2003; 97: 2203-2211.
19. Whiteside TL, Heo DS, Takagi S, Johnson JT, Iwatsuki S, Herberman RB,. Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2. Cancer Immunol Immunother 1988; 26: 1-10.
20. Rogner UC, Wilke K, Steck E, Korn B, Poustka A,. The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28. Genomics 1995; 29: 725-731.
21. Dutton C, Sommer SS,. Simultaneous detection of multiple single-base alleles at a polymorphic site. Biotechniques 1991; 11: 700-702.
22. Lin W, Zhang X, Chen Z, et al. Development and immunophenotyping of squamous cell carcinoma xenografts: tools for translational immunology. Laryngoscope 2005; 115: 1154-1162.
23. Lim HW, Hillsamer P, Banham AH, Kim CH,. Cutting edge: direct suppression of B cells by CD4+CD25+ regulatory T cells. J Immunol 2005; 175: 4180-4183.
24. Petrovsky N, Aguilar JC,. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004; 82: 488-496.
25. Montes CL, Chapoval AI, Nelson J, et al. Tumor-induced senescent T cells with suppressor function: a potential form of tumor immune evasion. Cancer Res 2008; 68: 870-879.
26. Wang Z, Hong J, Sun W, et al. Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. J Clin Invest 2006; 116: 2434-2441.
27. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358: 2698-2703.
28. Quezada SA, Simpson TR, Peggs KS, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207: 637-650.
29. Xie Y, Akpinarli A, Maris C, et al. Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010; 207: 651-667.
30. American Cancer Society Analytical Bulletin, The American Cancer Society, New York; 1985. pp 3-6.
31. Young MR,. Protective mechanisms of head and neck squamous cell carcinomas from immune assault. Head Neck 2006; 28: 462-470.
32. Fleischhauer K, Tanzarella S, Russo V, et al. Functional heterogeneity of HLA-A02 subtypes revealed by presentation of a MAGE-3-encoded peptide to cytotoxic T cell clones. J Immunol 1997; 159: 2513-2521.
33. Slingluff C, Yamshchikov G, Hogan K, et al. Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines. Ann Surg Oncol 2008; 15: 3538-3549.
34. Powell DJ Jr, Dudley ME, Robbins PF, Rosenberg SA,. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 2005; 105: 241-250.
35. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654-2666.
36. Ellis JM, Henson V, Slack R, Ng J, Hartzman RJ, Katovich Hurley C,. Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance of A02011 and identification of HLA-A0231. Hum Immunol 2000; 61: 334-340.